Steven Mah
Stock Analyst at TD Cowen
(2.23)
# 2,779
Out of 5,067 analysts
29
Total ratings
37.93%
Success rate
10.67%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $28.56 | +103.08% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $26.56 | +16.72% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $8.17 | +1,368.79% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $4.17 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $16.47 | +155.01% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $3.51 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.77 | +464.97% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.93 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $1.54 | +1,263.64% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $230.63 | -32.79% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $30.00 | +366.67% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $2.22 | +2,242.34% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $123.85 | +235.08% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $24.35 | +926.69% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $28.56
Upside: +103.08%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $26.56
Upside: +16.72%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $8.17
Upside: +1,368.79%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $4.17
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $16.47
Upside: +155.01%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.51
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.77
Upside: +464.97%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.93
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $1.54
Upside: +1,263.64%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $230.63
Upside: -32.79%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $30.00
Upside: +366.67%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $2.22
Upside: +2,242.34%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $123.85
Upside: +235.08%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $24.35
Upside: +926.69%